推荐方案A联合康妇炎胶囊治疗慢性盆腔炎50例临床观察  

Combined use of recommended scheme A and Kangfuyan capsule in chronic pelvic inflammatory disease

作　　者：周宏霞 黄华文[2] 文清华 ZHOU Hong-xia;HUANG Hua-wen;WEN Qing-hua(Department of Gynecology and Obstetrics,Lianjiang Hospital of Traditional Chinese Medicine;Department of Gynecology and Obstetrics,Lianjiang People􀆳s Hospital,Lianjiang 524400,China)

机构地区：[1]广东省廉江市中医院妇产科 [2]广东省廉江市人民医院妇产科,广东廉江524400

出　　处：《广东医科大学学报》2021年第5期634-637,共4页Journal of Guangdong Medical University

基　　金：湛江市科技计划项目(No.2020B01008)。

摘　　要：目的观察推荐方案A联合康妇炎胶囊治疗慢性盆腔炎(CPID)的疗效。方法100例CPID患者随机分为对照组和观察组,分别采用推荐方案A或推荐方案A联合康妇炎胶囊治疗。比较两组疗效、症状、血液流变学、炎症指标和不良反应。结果观察组疗效明显优于对照组(P<0.01),子宫及附件压痛、子宫活动受限、附件增厚、血液流变学指标、C反应蛋白水平、白细胞计数均明显低于对照组(P<0.05或0.01)。结论推荐方案A联合康妇炎胶囊治疗CPID可提高疗效,改善临床症状、血液流变学和抗炎效果。Objective To observe the clinical efficacy of recommended scheme A and Kangfuyan capsule in chronic pelvic inflammatory disease(CPID).Methods A total of 100 CPID patients were randomized to control and observation groups,and treated respectively with recommended scheme A or additional Kangfuyan capsule.Clinical efficacy,symptoms,hemorheology,inflammatory indexes and adverse reactions were compared between two groups.Results Compared with control group,clinical efficacy was better(P<0.01),while uterine and appendage tenderness,uterine activity restriction,appendage thickening,hemorheological parameters,C-reactive protein and leukocyte count were lower(P<0.01 or 0.05)in observation group.Conclusion Combined use of recommended scheme A and Kangfuyan capsule can improve clinical efficacy,symptoms,hemorheology and anti-inflammatory effect in CPID.

关 键 词：慢性盆腔炎 推荐方案A 康妇炎胶囊 

分 类 号：R711.33[医药卫生—妇产科学]